Latest Intelligence on Central Nervous System

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: yet more bad news for Pristiq

The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential.

Published By Datamonitor
10 Aug 2007
CommentWire
CommentWire

Wyeth: UK offers Efexor relief

Having concluded a new review of the latest safety evidence related to Wyeth's serotonin and noradrenergic reuptake inhibitor Efexor, UK regulators have eased the barriers restricting use of the drug. The updated prescribing advice should help Wyeth stabilize sales of Efexor while also enabling the company to plan more effectively for the launch of its follow-on compound, desvenlafaxine.

Published By Datamonitor
02 Jun 2006
CommentWire
CommentWire

Wyeth: Prempro linked with dementia

A recent study published in the Journal of the American Medical Association has shown that Wyeth's hormone combination therapy Prempro increases the risk of probable dementia in postmenopausal women aged 65 years or older. Further studies are needed to establish the role of estrogen therapies in the onset of Alzheimer's disease.

Published By Datamonitor
29 May 2003
CommentWire
CommentWire

Wyeth: not SAD about Effexor approval

The expanding versatility of Wyeth's blockbuster Effexor is key to its continued success. Sales should top $2 billion in 2003. However, competition is strong with large players including Pfizer and GlaxoSmithKline battling for a share of the lucrative mood disorders market. Nevertheless, Effexor's advantageous mechanism of action and convenient once-daily dosage will provide the edge over rivals.

Published By Datamonitor
13 Feb 2003
CommentWire
CommentWire

Wyeth: Enbrel inflames profits

Wyeth has reported positive second quarter earnings, thanks in part to strong demand for the arthritis treatment Enbrel. With its launch in Japan already boosting sales, even with a drop in the drug's hard-sell marketing post-Vioxx, it is expected to remain well-positioned to carry the fight to Centocor's competing Remicade.

Published By Datamonitor
21 Jul 2005
CommentWire
CommentWire

Wyeth: Effexor XR is deemed effective

Wyeth has released the findings of the study, which pooled together results of eight double-blind studies and compared Effexor XR to a leading serotonin selective re-uptake inhibitor. Although the drug's sales should be high it could suffer at the hands of strong competition from Lilly's duloxetine.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Wyeth: Effexor unsuitable for depressed children

Wyeth [WYE] has warned that its antidepressant Effexor (venlafaxine) is not effective for treating depression in children and teenagers, raising further concerns over the safety of prescribing antidepressants to children. However, due to the drug's ongoing success and growth it is unlikely this latest warning will have a significant effect on Effexor's sales.

Published By Datamonitor
08 Sep 2003
CommentWire
CommentWire

Wyeth & Elan: hope grows for Alzheimer's treatment

Shares in Wyeth and Elan have risen following the release of much anticipated results for Alzheimer's treatment bapineuzumab. Although the primary endpoint was not met, the results suggest that the product may slow disease progression in approximately half of patients with a specific genetic make-up.

Published By Datamonitor
18 Jun 2008
CommentWire
CommentWire

Women's mental health: no easy thinking, no easy solutions

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

Women's health: magnesium sulfate best for pre-eclampsia

Magnesium sulfate has long been used to treat of pre-eclampsia, but there has been a lack of statistically significant clinical trial evidence to support this. This means other drugs, including aspirin and Pfizer's Dilantin, have often been used instead. However, according to the new trial, magnesium sulfate is the most effective and cost-effective treatment option.

Published By Datamonitor
31 May 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.